Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer

Introduction: For most locally advanced non–small cell lung cancer (LA-NSCLC) patients who complete definitive chemoradiotherapy (CRT) and do not experience disease progression, one year of adjuvant durvalumab is recommended. Here, we explore causes and consequences of early durvalumab discontinuati...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Michael Pennock, Balazs Halmos, William Bodner, Haiying Cheng, Rasim Gucalp, Nitin Ohri
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Elsevier 2023-07-01
Sarja:	Clinical and Translational Radiation Oncology
Aiheet:	Lung cancer Immunotherapy Radiotherapy Durvalumab Toxicity Prognosis
Linkit:	http://www.sciencedirect.com/science/article/pii/S240563082300068X
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!